New Data Confirm That Use of Levemir Can Limit Weight Gain ( lished that even modestweight loss is ...)

New Data Confirm That Use of Levemir Can Limit Weight Gain

lished that even modest weight loss is associated with improvement in blood glucose control, insulin sensitivity and the cardiovascular risk profile.(4-9)

The unique weight benefit of Levemir® has been reported in every single clinical trial published where it has been compared to other basal insulins.(10-23) Collectively these trials provide data representing more than 4,000 patients. In two recently published randomised clinical trials that investigated insulin initiation in type 2 diabetes, mean weight gain was reduced by more than 50% when comparing Levemir® to equivalent regimens of NPH insulin.(10,11) Furthermore, the relative weight benefit of Levemir® was shown to increase with increasing body mass index (BMI).(11) Thus, the weight advantage of Levemir® tended to be more pronounced in more overweight patients.

For further information please contact

Michael Laub

Tel: (+45) 4442 1960

About Levemir®

Levemir® is a long-acting modern insulin (insulin analogue) that covers the body’s basal insulin needs. Levemir® is released gradually from the injection site into the circulation. Compared to conventional long-acting insulins such as NPH insulin, Levemir® causes less fluctuation in blood glucose levels across the day and has greater predictability, ie a blood glucose lowering effect that is consistent from one injection to another. A single daily dose of Levemir® will provide a duration of action up to 24 hours.(24) The dose should be taken in the evening, at dinner or before bedtime. Injections can easily be managed with the simple and discreet FlexPen®, a prefilled insulin pen.(26,27)

About Novo Nordisk

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addit
'"/>

Page: 1 2 3 4 5 6
Related medicine technology :

1. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
4. MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy
5. New Data Confirms Significant Improvement of Disease Signs and Symptoms in Patients with Rheumatoid Arthritis
6. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
7. New Research Confirms the Benefit of Extended-Release Dipyridamole Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk Patients
8. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
9. Positive Clinical Data on CC-10004 Confirms Potential as Novel Oral Approach to Treating Inflammatory Diseases
10. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
11. Efficacy and Safety Profile of Basileas Alitretinoin for Severe Refractory Chronic Hand Eczema Confirmed by Data Shown at European Dermatology Congress

Post Your Comments:

( lished that even modestweight loss is ...)New Data Confirm That Use of Levemir Can Limit Weight Gain,Health